Trovagene, NWU Institutions Partner to Assess Oncogene Mutation Monitoring Tech | GenomeWeb

NEW YORK (GenomeWeb) — Trovagene has entered into a strategic partnership with two Northwestern University institutions to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.

Under the alliance, the Robert H. Lurie Comprehensive Care Center and the Northwestern Medicine Developmental Therapeutics Institute will work with Trovagene on clinical protocols that incorporate oncogene mutation monitoring during the course of cancer treatment, and assess their impact on overall disease management and patient outcomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.